Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06122987 · ClinicalTrials.gov registry record · Phase 4
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
A Phase 4 study of Sepsis and Septic Shock, sponsored by Kingman Regional Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06122987: Recruiting Phase 4 study of Sepsis and Septic Shock, sponsored by Kingman Regional Medical Center.
NCT06122987 is a Phase 4 study of Sepsis and Septic Shock that is actively recruiting participants, run by Kingman Regional Medical Center. The registered enrollment target is 50 participants, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06122987, a Phase 4 study of Sepsis and Septic Shock, is actively recruiting participants, sponsored by Kingman Regional Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Norepinephrine is a catecholamine that is the first-line vasopressor for septic shock. The addition of non-catecholamine vasopressors, including vasopressin and angiotensin-II may be used in adults with septic shock that have inadequate mean arterial pressure while on norepinephrine. Uncertainty exists regarding the timing of initiation of these agents and there is a lack of data comparing their safety and efficacy. The current literature suggests that earlier initiation of angiotensin-II will have a more significant reduction on norepinephrine-equivalent dose compared to later initiation. In addition, approximately half of patients initiated on vasopressin do not have an early hemodynamic response 6 hours after initiation. The purpose of this study is to evaluate the efficacy of angiotensin-II when used as the second vasopressor agent for septic shock.
Conditions Studied
Interventions
- DRUG Angiotensin II and hydrocortisone sodium succinate
Study Locations (1)
Arizona
- Kingman Regional Medical Center - Kingman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-12-04 |
| Est. Completion | 2025-01 |
| Phase | Phase 4 |
What NCT06122987 shows while recruiting
NCT06122987 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which Angiotensin II and hydrocortisone sodium succinate is the first listed.
NCT06122987 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06122987 about?
NCT06122987 is a clinical study titled "Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock". Norepinephrine is a catecholamine that is the first-line vasopressor for septic shock. The addition of non-catecholamine vasopressors, including vasopressin and angiotensin-II may be used in adults with septic shock that have inadequate mean arterial pressure while on norepinephrine. Uncertainty exi...
What is the current status of trial NCT06122987?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2023-12-04. Estimated completion is 2025-01.
What conditions does trial NCT06122987 study?
This clinical trial studies the following conditions: Sepsis, Septic Shock, Shock, Systemic Inflammatory Response Syndrome.
What interventions are being tested in trial NCT06122987?
The interventions under investigation include: Angiotensin II and hydrocortisone sodium succinate (DRUG).
Who is sponsoring clinical trial NCT06122987?
This trial is sponsored by Kingman Regional Medical Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06122987 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06122987's enrollment target sits among peer trials
50 72nd of 90 higher than 16 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
The PASTDUe Nutrition Ecosystem Project (PASTDUe)
ACTIVE NOT RECRUITING · Phase 4
-
Effect of Nebulized Bronchodilators on Heart Rate
COMPLETED · Phase 4
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI